KeyCorp Initiates Coverage on Lifecore Biomedical (NASDAQ:LFCR)

Key Points

• KeyCorp has initiated coverage on Lifecore Biomedical (NASDAQ:LFCR) with a sector weight rating, following similar coverage from other firms such as William Blair, which assigned an outperform rating.
• Lifecore Biomedical reported a quarterly loss of ($0.10) earnings per share, slightly missing expectations, while its revenue reached $36.44 million, exceeding analyst forecasts.
• Institutional investors own 83.36% of Lifecore Biomedical’s stock, with several firms like MIRAE ASSET GLOBAL increasing their holdings recently.

KeyCorp started coverage on shares of Lifecore Biomedical (NASDAQ:LFCR - Free Report) in a research note published on Wednesday, MarketBeat reports. The brokerage issued a sector weight rating on the stock. KeyCorp also issued estimates for Lifecore Biomedical's Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.46) EPS.

A number of other research firms have also recently issued reports on LFCR. Wall Street Zen raised shares of Lifecore Biomedical from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. William Blair began coverage on shares of Lifecore Biomedical in a research note on Wednesday, May 21st. They issued an "outperform" rating on the stock. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Lifecore Biomedical has an average rating of "Moderate Buy" and an average price target of $8.00.

Lifecore Biomedical Stock Performance

LFCR traded down $0.41 on Wednesday, reaching $7.53. The stock had a trading volume of 138,549 shares, compared to its average volume of 106,325. Lifecore Biomedical has a 12-month low of $4.33 and a 12-month high of $8.85. The company has a current ratio of 2.84, a quick ratio of 1.77 and a debt-to-equity ratio of 113.76. The business's 50-day moving average price is $7.62 and its two-hundred day moving average price is $6.93. The company has a market cap of $281.70 million, a P/E ratio of -5.75 and a beta of 0.64.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. The firm had revenue of $36.44 million during the quarter, compared to analysts' expectations of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS. Sell-side analysts forecast that Lifecore Biomedical will post -0.91 earnings per share for the current year.

Institutional Trading of Lifecore Biomedical

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in Lifecore Biomedical by 1,839.7% during the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock valued at $25,000 after acquiring an additional 3,385 shares in the last quarter. Summit Securities Group LLC acquired a new position in shares of Lifecore Biomedical during the 1st quarter valued at about $26,000. Hurley Capital LLC acquired a new position in shares of Lifecore Biomedical during the 1st quarter valued at about $35,000. State of Wyoming acquired a new position in shares of Lifecore Biomedical during the 2nd quarter valued at about $69,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Lifecore Biomedical during the 2nd quarter valued at about $88,000. Hedge funds and other institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.